Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
|Articles|February 26, 2022
Writing for General Readers
Author(s)William H. Reid, MD, MPH
“Most people say that pretty much all physicians have a book inside them—and I agree.”
Advertisement
Writing for general readers can be a very rewarding experience. In this installment of More Than Medicine, William H. Reid, MD, MPH, walks us through the process of writing and publishing fiction and nonfiction books, plus how you can get started.
Dr Reid is a forensic psychiatrist in Horseshoe Bay, Texas. He is the author of
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
New Adult ADHD Guidelines: What Resources Are Coming Soon
3
Vol 43, Issue 9 - Interactive
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5